NCT03720613View on ClinicalTrials.gov

Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation

RecruitingOBSERVATIONAL
Enrollment

34,532

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

November 1, 2030

Study Completion Date

November 1, 2030

Conditions
Opioid-induced Constipation
Interventions
DRUG

Naldemedine

0.2 mg tablet once a day at any time with or without food

DRUG

Lubiprostone

0.024 mg twice a day \[adjust dose based on liver function\]

DRUG

Naloxegol

25 mg tablet once a day in morning, 1 hour before or 2 hours after food

Trial Locations (1)

19801

RECRUITING

Research Site, Wilmington

Sponsors
All Listed Sponsors
collaborator

HealthCore, Inc.

INDUSTRY

lead

BioDelivery Sciences International

INDUSTRY